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Patients with Atrial Fibrillation Undergoing Total
Joint Arthroplasty Increase Hospital Burden
Vinay K. Aggarwal, BA, Eric H. Tischler, BA, Zachary D. Post, MD, Ian Kane, BS, Fabio R. Orozco, MD, and Alvin Ong, MD
Investigation performed at The Rothman Institute of Orthopedics at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Background: More than 3 million people in the United States have atrial fibrillation, most of whom are being managed
with anticoagulation therapy for life. The goal of the present study was to examine the effect of chronic anticoagulation
therapy on patients with atrial fibrillation who undergo total joint arthroplasty.
Methods: We retrospectively reviewed all patients undergoing aseptic primary or revision total joint arthroplasty at our
facility from March 2007 to August 2011. One hundred and sixty-one patients with atrial fibrillation (Group A) were
compared with 161 matched controls (Group B). A total of 112 hips and 210 knees underwent 239 primary arthroplasties
and eighty-three revisions. The groups were compared with use of conditional logistic regression (with matching on the
basis of the involved joint [hip or knee], type of procedure [revision or primary], age, and sex) with regard to the length of
hospital stay, postoperative hemoglobin levels, transfusion requirements, and readmissions.
Results: The preoperative length of stay (1.7 versus 0.2 days; p < 0.0001), postoperative length of stay (4.6 versus
3.2 days; p = 0.0002), and total length of stay (6.3 versus 3.4 days; p < 0.0001) were significantly longer for patients with
atrial fibrillation (Group A). Hemoglobin levels were lower (but not significantly so) for Group A at baseline (13.1 versus
13.8 mg/dL), on Postoperative Day 2 (10.1 versus 10.6 mg/dL), on Postoperative Day 3 (9.8 versus 10.2 mg/dL), on
Postoperative Day 4 (9.6 versus 10.1 mg/dL), on Postoperative Day 5 (9.7 versus 9.9 mg/dL), and at discharge (9.9
versus 10.3 mg/dL). Group A had a significantly higher prevalence of blood transfusion (15.5% versus 3.7%; p = 0.0005)
and periprosthetic joint infection (5.6% versus 0.62%; p = 0.0196). A diagnosis of atrial fibrillation (odds ratio, 4.09; 95%
confidence interval, 2.05 to 8.18; p < 0.0001) significantly increased the odds of total joint arthroplasty complication and
the need for hospital readmission.
Conclusions: Patients with preoperative atrial fibrillation undergoing total joint arthroplasty had an increased length of
hospital stay, increased transfusion requirements, and an increased risk of periprosthetic joint infection and unplanned
hospital readmission.
Level of Evidence: Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.

A

trial fibrillation is the most common chronic cardiac
arrhythmia in the United States, occurring in an estimated 3.2 million people in 20051,2. It has been projected
that by the year 2050, the number of Americans with atrial
fibrillation will increase to almost 8 million2. The prevalence
of this cardiac dysrhythmia increases dramatically in the elderly
population, to 9.0% in persons eighty years of age or older3.
At a time when health-care costs are increasingly scrutinized,
the economic and health-care burdens of patients with atrial

fibrillation are approximately five times those of patients without atrial fibrillation4. In 2005, an estimated $6.65 billion was
spent on the treatment of patients who have this condition in the
United States5.
Much of this health-care burden is due to the additional
medical utilization associated with chronic anticoagulation therapy, which is lifelong for most individuals with atrial fibrillation6,7.
The American College of Chest Physicians (ACCP) recommends
that patients with atrial fibrillation receive high-dose aspirin or
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TABLE I Demographic Variables

Demographic Variables

Atrial Fibrillation
Group (N = 161)

Control Group (N = 161)

P Value

Age* (yr)

72.8

69.0

0.03

Male

50.3%

54.0%

0.577

BMI* (kg/m2)

31.2

30.4

0.589

Index procedure
Knee
Primary

65.8%
76.4%

64.6%
72.0%

0.695
0.447

*The values are given as the mean.

warfarin anticoagulation therapy, depending on their risk factors
for a thrombotic event8,9. For patients receiving warfarin, the
international normalized ratio (INR) is kept in the range from
2.0 to 3.0, placing elderly patients at a major risk for bleeding
events such as intracranial hemmorhage10. In addition, patients
receiving anticoagulation therapy who have surgery are at increased
risk for persistent wound drainage and hematoma formation11.
These issues pose major problems for patients with chronic
atrial fibrillation who undergo total joint arthroplasty. While
adequate anticoagulation therapy is required for these patients to
prevent thrombotic events such as cerebrovascular accident,
the elevated INR required in these patients puts them at considerable risk for bleeding12. It is well established that bleeding
complications create an increased potential for delayed woundhealing, functional disability, and periprosthetic joint infection11,13. To minimize these risks, patients with atrial fibrillation
are sometimes admitted to the hospital prior to surgery in order
to wean them from anticoagulation therapy and to normalize INR
levels14-16. The additional care provided for patients with atrial fibrillation even after total joint arthroplasty may pose a substantial
increase in the health-care burden. We are aware of no study that
has examined this subset of patients undergoing arthroplasty.
The primary goal of our case-controlled study was to examine the effect of atrial fibrillation and chronic anticoagulation
therapy on hospital burden for patients undergoing total joint
arthroplasty. Outcome measures evaluated included the length
of stay in the hospital, postoperative anemia, blood transfusion
requirements, and hospital readmission due to surgery-related
complications.

body mass index (BMI), surgeon, postoperative prophylaxis against deep-vein
thrombosis, and approximate date of surgery. Matched variables were chosen to
eliminate their potential confounding effects on study outcomes. Revision was
defined as partial or complete removal or exchange of the components. The exclusion criteria were bilateral total joint arthroplasty, revision for the treatment of
infection at the site of the total joint arthroplasty, or less than six months of followup after the procedure of interest.
All arthroplasties in both patient groups were performed from 2007 to
2011 by two senior surgeons (A.O. and F.R.O.) at a single, high-volume institution. Preoperatively, all patients with atrial fibrillation were receiving either anticoagulation therapy with warfarin (used for approximately 90% of patients with
atrial fibrillation) or other chronic therapy with aspirin, clopidogrel, or dabigatran
(used for approximately 10% of patients with atrial fibrillation). The institutional
hospital protocol was to preadmit all patients with atrial fibrillation who were
receiving chronic warfarin therapy one day prior to surgery in order to ensure a
normal INR level. Once warfarin was discontinued, these patients were managed
with heparin bridging until six hours before surgery. Patients receiving alternative
chronic treatment for atrial fibrillation were asked not to take medication at least
seven days prior to surgery but were not admitted to the hospital prior to the date
of surgery. All patients in both the study and control groups were managed with
warfarin for anticoagulation after surgery.
Overall, 161 joints (fifty-five hips and 106 knees) in 161 consecutive
patients with atrial fibrillation were matched with 161 joints (fifty-seven hips
and 104 knees) in 161 control patients without atrial fibrillation. There were
eighty-one men (50.3%) in the atrial fibrillation group and eighty-seven men

TABLE II Reasons for Readmission in Patients with and without
Atrial Fibrillation*

Reason for Readmission

Atrial Fibrillation
Group

Control
Group

Periprosthetic joint infection

9

1

Materials and Methods

Wound complication

7

1

W

Mechanical joint failure

8

7

Cardiopulmonary event

7

1

Gastrointestinal complication

4

0

Atrial fibrillation episode

4

0

Other

2

0

Total

41

10

e performed a retrospective case-controlled study with a one-to-one ratio
of cases and matched controls. Using our institutional electronic database,
we identified all patients with a preexisting diagnosis of atrial fibrillation undergoing aseptic primary or revision total hip or knee arthroplasty at our institution
during a four-year span from March 2007 to September 2011. More than 3000
total joint arthroplasty procedures were performed at the institution during the
study period.
For each patient with atrial fibrillation, we aimed to identify one matching
patient without atrial fibrillation as a control. This control population was derived
with use of our electronic database by matching for the following variables: age,
sex, involved joint (hip or knee), laterality, procedure type (primary or revision),
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TABLE III Effect of Atrial Fibrillation on Blood Transfusion
and Readmission Rate Using Matched Conditional
Logistic Regression Analysis*

Variable

Odds
Ratio

95% Confidence
Interval

Blood transfusion

5.75

1.99 to 16.65

0.0012

Readmission rate

4.09

2.05 to 8.18

<0.0001

P Value

*Adjusted for age as a potential confounder.

(54.0%) in the control group. The mean age was 72.8 years for the atrial fibrillation group and 69.0 years for the control group. The mean BMI was 31.2 for the
atrial fibrillation group and 30.4 for the control group. There were 123 primary
procedures (76.4%) and thirty-eight revision procedures (23.6%) in the atrial
fibrillation group, compared with 116 primary procedures (72.0%) and forty-five
revision procedures (28.0%) in the control group. The baseline characteristics
other than age were not significantly different between the two groups (Table I).
A thorough chart review utilizing electronic medical records was used to
ascertain information regarding outcomes of interest. The primary outcome of
our study analysis was hospital burden as measured on the basis of preoperative,
postoperative, and total length of stay. The preoperative length of stay was
defined as the interval between hospital admission and surgery start time, the
postoperative length of stay was defined as the interval between surgery start time
and hospital discharge time, and the total length of stay was defined as the interval
between hospital admission and hospital discharge time. The presence of postoperative anemia was assessed through the measurement of hemoglobin (Hgb)
levels at baseline (prior to surgery), on Postoperative Days 1 through 5, and on
the day of discharge. Additionally, the INR at the time of discharge was recorded

P AT I E N T S W I T H A T R I A L F I B R I L L AT I O N U N D E R G O I N G T O TA L J O I N T
A R T H R O P L A S T Y I N C R E A S E H O S P I TA L B U R D E N

for the evaluation of anticoagulation therapy and bleeding risk in both groups.
Blood transfusion requirements were recorded as binary variables based on the
need for allogeneic postoperative red blood cell transfusion as compared with no
need for transfusion. Finally, complications and readmissions following discharge from the hospital for reasons related to the surgical procedure or the
diagnosis of atrial fibrillation were obtained from a review of medical records.
Means and frequencies were calculated for continuous and categorical
variables, respectively. The length of hospital stay was reported as the mean and
the standard deviation (in days). Hemoglobin levels were reported as the mean
(in mg/dL). The need for blood transfusion and the readmission rate were
modeled with use of conditional logistic regression. Conditional logistic
regression was used as all patients were matched for potentially confounding
variables of joint (hip or knee), age, sex, and procedure (primary or revision).

Source of Funding
No external funding was received for this study.

Results
he preoperative, postoperative, and total lengths of stay
were all significantly associated with the diagnosis of preexisting atrial fibrillation. The mean preoperative length of stay
(and standard deviation) was 1.7 ± 0.7 days for patients with
atrial fibrillation and 0.2 ± 0.2 day for patients without atrial
fibrillation (p < 0.0001). The mean postoperative length of stay
was 4.6 ± 4.6 days for patients with atrial fibrillation and 3.2 ±
1.1 days for patients without atrial fibrillation (p = 0.0002).
The mean total length of stay was 6.3 ± 4.7 days for patients
with atrial fibrillation and 3.4 ± 1.1 days for patients without
atrial fibrillation (p < 0.0001).

T

Fig. 1

Line graph showing that the mean hemoglobin level for patients with atrial fibrillation (AF) was slightly lower on all days of hospitalization except for
Postoperative Day (POD) 1. No differences reached significance.
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TABLE IV Complications Following Total Joint Arthroplasty
Complication Category
Periprosthetic joint
infection
Cardiovascular
Wound
Bleeding event
Mechanical joint
failure
Sepsis/cardiogenic shock

Atrial Fibrillation Group*

Control Group*

P Value

9

1

0.0196

12

6

0.2244

7

2

0.1735

7

0

0.0146

11

7

0.4678

5

0

0.0606

Other

11

2

0.0199

Total

62

18

<0.0001

*The values are given as the number of patients.

The mean hemoglobin levels on the day of admission
(baseline), on Postoperative Days 1 through 5, and on the day of
discharge did not differ significantly between the groups (Fig. 1).
At the time of discharge, the INR for patients with atrial fibrillation
was nontherapeutic and was not significantly different from that
for patients without atrial fibrillation (1.8 versus 1.7; p = 0.1176).
The prevalence of blood transfusion was 15.5% (twentyfive of 161) for patients with atrial fibrillation and 3.7% (six
of 161) for patients without atrial fibrillation (p = 0.0005). Fortyone (25.5%) of the 161 patients with atrial fibrillation had an
unplanned readmission related to surgery, whereas just ten
(6.2%) of the 161 patients without atrial fibrillation were
readmitted (p < 0.0001) (Table II). A diagnosis of atrial fibrillation increased the odds of blood transfusion by 5.75 times
(95% confidence interval [CI], 1.99 to 16.65) (p = 0.0012)
and increased the odds of unplanned readmission by 4.09
times (95% CI, 2.05 to 8.18) (p < 0.0001) (Table III).
The overall rate of complications related to total joint
arthroplasty surgery was significantly greater in the atrial fibrillation group (38.5% versus 11.2%; p < 0.0001). Table IV shows
all complications in both groups by category. Cardiovascular
complications included hypotension, bradycardia, tachycardia,
congestive heart failure, arrhythmic episode, or myocardial infarction requiring some form of acute in-hospital treatment.
Wound-related complications included hematoma formation, dehiscence, cellulitis, or superficial infection. Mechanical
joint complications included arthrofibrosis, aseptic prosthetic
loosening, joint instability, and knee extensor mechanism failure.
Bleeding events included hematuria, gastrointestinal bleeding,
and blood in the stool. Of the five patients in the atrial fibrillation
group who experienced septic or cardiogenic shock, two died.
The ‘‘other’’ category included painful paresthesias, urinary retention, urinary tract infection, postoperative pneumonia, and
gastrointestinal upset.
Discussion
trial fibrillation is a common cardiac comorbidity that
carries a one-in-four lifetime risk of development for both

A

men and women forty years of age and older1. This condition
predominantly affects the elderly, with a mean age of 66.8 years in
men and 74.6 years in women17. Kurtz et al. reported that the
demand for all arthroplasty procedures is projected to grow
dramatically over the next several decades18,19. Their analysis
showed that elderly patients in the sixty-five to eighty-four-yearold age group are expected to have considerably higher rates of
total joint arthroplasty procedures than younger patients are. We
are aware of no studies regarding the additional costs associated
with the management of patients with atrial fibrillation who
undergo total joint arthroplasty. The purpose of the present
study was to evaluate this increased health-care burden with use
of a case-controlled matched study of patients at our institution.
Our study illustrates the considerable additional economic
cost associated with caring for patients with preexisting atrial
fibrillation who undergo total joint arthroplasty. The mean
preoperative, postoperative, and total lengths of stay were significantly longer in this group. Other medical specialties have
reported on hospital stay and associated costs for patients with
atrial fibrillation. In a cohort of patients hospitalized with atrial
fibrillation as a secondary discharge diagnosis, Song et al. showed
a similar increase in the mean length of stay (1.84 days longer)
and hospital cost ($3146 greater)7. In patients undergoing coronary artery bypass surgery, several studies have identified atrial
fibrillation as a strong independent predictor of hospital stay
prolongation after surgery6,20. These findings are all in agreement
with the analysis of our data. However, those studies highlight the
complications that can occur as the result of an episode of atrial
fibrillation in the hospital and do not focus on the surgical risks
and considerations pertaining to patients with preexisting atrial
fibrillation.
A major reason for the increased hospital burden associated with patients with atrial fibrillation who undergo total joint
arthroplasty is the delicate balance of their anticoagulation therapy. Not only does it take almost four days for the antithrombotic
effect of warfarin to recede, but three days are also typically required to reestablish therapeutic anticoagulation after resuming
the medication16. Although not universally practiced across the
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country, at our institution we preadmit patients who are receiving
anticoagulation therapy in order to ensure that a safe INR is
obtained for surgery. The ACCP guidelines for patients with
atrial fibrillation who require temporary interruption in warfarin
therapy state that bridging anticoagulation with heparin is recommended for patients with high thromboembolic risk or for
those undergoing high-risk procedures21. Although many consider total joint arthroplasty to be a procedure that is associated
with a high risk of thrombotic and bleeding events, Chana et al.
and Rhodes et al. suggested that interruption of warfarin therapy
is not required during joint arthroplasty and does not lead to a
higher rate of complications22,23. As these were both small retrospective studies with few patients (twenty-four and thirty-eight
patients, respectively), we suggest that larger clinical trials in
patients undergoing total joint arthroplasty will provide more
definitive guidance for perioperative anticoagulation management of patients who have atrial fibrillation24.
The management of patients who have atrial fibrillation
and undergo total joint arthroplasty is burdensome not only
because of the increased length of stay in the hospital associated
with anticoagulation but also because of risks associated with
greater postoperative bleeding. In the present study, increased
bleeding was reflected by postoperative anemia and higher blood
transfusion rates. Parvizi et al. reported that excessive postoperative bleeding complications, such as hematoma formation and
wound drainage, were significant risk factors for the development
of periprosthetic joint infection11. In addition, Pulido et al. found
that allogeneic blood transfusion after surgery was an independent predisposing risk factor for periprosthetic joint infection,
with an odds ratio (OR) of 2.11 (p = 0.02)25. While it was beyond
the scope of the present study to analyze the direct correlation
between blood loss or transfusion and periprosthetic joint infection, we did find that the prevalence of periprosthetic joint
infection was 5.6% (nine of 161) in the atrial fibrillation group,
compared with 0.62% (one of 161) in the control group (p =
0.0196). To demonstrate the dangers of blood loss further,
the use of allogeneic blood transfusion also has been linked
to a 3.5-times greater likelihood of admission to the intensive
care unit after total joint arthroplasty26.
We found that a diagnosis of atrial fibrillation significantly
increased the odds of hospital readmission after discharge following total joint arthroplasty (OR, 4.09; 95% CI, 2.05 to 8.18).
In the present health-care environment, reimbursements will
soon be tied to high-quality, efficient care, otherwise known as
pay-for-performance. Orthopaedic surgeons who perform total
joint arthroplasty and whose practice includes patients with
atrial fibrillation may be adversely affected by the increased rate
of unplanned readmission that we found. Rather than deny joint
reconstruction procedures to this patient population, surgeons
must instead focus on the prevention of complications. A com-

P AT I E N T S W I T H A T R I A L F I B R I L L AT I O N U N D E R G O I N G T O TA L J O I N T
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mentary by Bozic et al. suggested that with newer reimbursement
policies in orthopaedic practices, medical treatment may suffer
because of inevitable health-care provider gaming and patient
deselection, placing the burden on lower-tier, lower-quality
providers27. Our goal in presenting this study is to highlight
the issues that orthopaedic surgeons face when patients with
atrial fibrillation are candidates for total joint arthroplasty.
The limitations of the present study are inherent to its
retrospective design. Because the majority of our patients were
receiving warfarin for the treatment of chronic atrial fibrillation,
we were unable to evaluate the effect of newer medications such
as dabigatran on the postoperative parameters studied. Nonetheless, our study is in accordance with previous literature on the
challenges that patients with atrial fibrillation pose as the population continues to age. In addition, we utilized a matched casecontrolled study design to ensure that we accounted for as many
potentially confounding risk factors as possible. One additional
limitation is that because all arthroplasties were limited to one
institution and were performed by only two surgeons, it may be
difficult to generalize the results from our analysis. However, our homogenous patient population and standardized
surgical protocol ensured a reliable comparison between
the two patient groups being examined. Finally, because of
a lack of literature surrounding this topic, we were unable
to make direct comparisons with other studies of patients
with preexisting atrial fibrillation who underwent total joint
arthroplasty.
In conclusion, patients with preoperative atrial fibrillation who underwent total joint arthroplasty at our institution
had increased length of hospital stay, increased postoperative
anemia and transfusion requirements, and an increased risk of
complications and unplanned readmissions. As complications
and readmissions can negatively affect hospital and physician
reimbursement, we recommend increased surveillance of these
patients with atrial fibrillation to appropriately manage expectations and to decrease complication rates. n

Vinay K. Aggarwal, BA
Eric H. Tischler, BA
Zachary D. Post, MD
Ian Kane, BS
Fabio R. Orozco, MD
Alvin Ong, MD
The Rothman Institute of Orthopedics
at Thomas Jefferson University Hospital,
925 Chestnut Street,
2nd Floor, Philadelphia, PA 19107.
E-mail address for V.K. Aggarwal: vinayagg1@gmail.com.
E-mail address for A. Ong: Alvin.Ong@rothmaninstitute.com

References
1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D’Agostino RB,
Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of
atrial fibrillation: the Framingham Heart Study. Circulation. 2004 Aug 31;110(9):
1042-6. Epub 2004 Aug 16.

2. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009 Dec 1;104(11):1534-9.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm

Downloaded From: http://jbjs.org/ by a Thomas Jefferson University User on 12/08/2013

1611
TH E JO U R NA L O F B O N E & JO I N T SU RG E RY J B J S . O RG
V O LU M E 95-A N U M B E R 17 S E P T E M B E R 4, 2 013
d

d

d

management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.
4. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.
Economic burden and co-morbidities of atrial fibrillation in a privately insured
population. Curr Med Res Opin. 2005 Oct;21(10):1693-9.
5. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P.
Assessing the direct costs of treating nonvalvular atrial fibrillation in the United
States. Value Health. 2006 Sep-Oct;9(5):348-56.
6. Tamis JE, Steinberg JS. Atrial fibrillation independently prolongs hospital stay
after coronary artery bypass surgery. Clin Cardiol. 2000 Mar;23(3):155-9.
7. Song X, Sander SD, Johnson BH, Varker H, Amin AN. Impact of atrial fibrillation
and oral anticoagulation on hospital costs and length of stay. Am J Health Syst
Pharm. 2012 Feb 15;69(4):329-38.
8. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL,
Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V,
Rydén LE, Cannom DS, Le Heuzey JY, Crijns HJ, Lowe JE, Curtis AB, Olsson S,
Ellenbogen KA, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Wann L, Jacobs AK,
Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM,
Ettinger SM, Stevenson WG, Guyton RA, Tarkington LG, Halperin JL, Yancy CW; 2011
Writing Group Members; 2006 Writing Committee Members; ACCF/AHA Task Force
Members. 2011 ACCF/AHA/HRS focused update on the management of patients
with atrial fibrillation (updating the 2006 guideline): a report of the American College
of Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines. Circulation. 2011 Jan 4;123(1):104-23. Epub 2010 Dec 20.
9. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning
WJ; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):546S-592S.
10. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE.
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among
patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov
16;141(10):745-52.
11. Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does ‘‘excessive’’ anticoagulation predispose to periprosthetic infection? J Arthroplasty.
2007 Sep;22(6)(Suppl 2):24-8. Epub 2007 Jul 26.
12. Pellegrini VD Jr, Sharrock NE, Paiement GD, Morris R, Warwick DJ. Venous
thromboembolic disease after total hip and knee arthroplasty: current perspectives
in a regulated environment. Instr Course Lect. 2008;57:637-61.
13. Cheung EV, Sperling JW, Cofield RH. Infection associated with hematoma formation after shoulder arthroplasty. Clin Orthop Relat Res. 2008 Jun;466(6):1363-7.
Epub 2008 Apr 18.
14. Jafri SM, Mehta TP. Periprocedural management of anticoagulation in
patients on extended warfarin therapy. Semin Thromb Hemost. 2004 Dec;30(6):
657-64.
15. Krahn AD, Healey JS, Simpson CS, Essebag V, Sivakumaran S, Birnie DH.
Anticoagulation of patients on chronic warfarin undergoing arrhythmia device sur-

P AT I E N T S W I T H A T R I A L F I B R I L L AT I O N U N D E R G O I N G T O TA L J O I N T
A R T H R O P L A S T Y I N C R E A S E H O S P I TA L B U R D E N

gery: wide variability of perioperative bridging in Canada. Heart Rhythm. 2009
Sep;6(9):1276-9. Epub 2009 Jun 06.
16. Kearon C, Hirsh J. Management of anticoagulation before and after elective
surgery. N Engl J Med. 1997 May 22;336(21):1506-11.
17. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon
MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ,
Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT,
Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB,
McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter
NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, WylieRosett J; American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Heart disease and stroke statistics—2011 update: a report from the
American Heart Association. Circulation. 2011 Feb 1;123(4):e18-209. Epub 2010
Dec 15.
18. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision
hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg
Am. 2007 Apr;89(4):780-5.
19. Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M. Prevalence of primary and
revision total hip and knee arthroplasty in the United States from 1990 through
2002. J Bone Joint Surg Am. 2005 Jul;87(7):1487-97.
20. Auer J, Weber T, Berent R, Ng CK, Lamm G, Eber B. Postoperative atrial fibrillation independently predicts prolongation of hospital stay after cardiac surgery.
J Cardiovasc Surg (Torino). 2005 Dec;46(6):583-8.
21. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn
AS, Kunz R; American College of Chest Physicians. Perioperative management of
antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th
ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e326S-50S.
22. Chana R, Salmon L, Waller A, Pinczewski L. Warfarin management in patients on
continuous anticoagulation therapy undergoing total knee replacement. J Bone Joint
Surg Br. 2011 Nov;93(11):1497-502.
23. Rhodes DA, Severson EP, Hodrick JT, Dunn HK, Hofmann AA. Discontinuation of
warfarin is unnecessary in total knee arthroplasty. Clin Orthop Relat Res. 2010
Jan;468(1):120-6.
24. Garwood CL, Hwang JM, Moser LR. Striking a balance between the risks and
benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical
updates and remaining controversies. Pharmacotherapy. 2011 Dec;31(12):1208-20.
25. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. Periprosthetic joint infection: the
incidence, timing, and predisposing factors. Clin Orthop Relat Res. 2008
Jul;466(7):1710-5. Epub 2008 Apr 18.
26. Abdelsalam H, Restrepo C, Tarity TD, Sangster W, Parvizi J. Predictors of intensive care unit admission after total joint arthroplasty. J Arthroplasty. 2012
May;27(5):720-5.
27. Bozic KJ, Smith AR, Mauerhan DR. Pay-for-performance in orthopedics: implications for clinical practice. J Arthroplasty. 2007 Sep;22(6)(Suppl 2):8-12. Epub
2007 Jul 26.

Downloaded From: http://jbjs.org/ by a Thomas Jefferson University User on 12/08/2013

